Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study.

Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, Gallo C, Giunta FP, Fraternali A, Salvo D, Asti M, Azzolini F, Iori V, Sassatelli R.

Clin Nucl Med. 2010 May;35(5):321-8. doi: 10.1097/RLU.0b013e3181d6677c.

PMID:
20395703
2.

Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.

Nakamoto Y, Sano K, Ishimori T, Ueda M, Temma T, Saji H, Togashi K.

Ann Nucl Med. 2015 Jul;29(6):512-8. doi: 10.1007/s12149-015-0973-7. Epub 2015 Apr 18.

3.

Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

Recent Results Cancer Res. 2013;194:353-71. doi: 10.1007/978-3-642-27994-2_18.

PMID:
22918768
4.

Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.

Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, Prasad V, Hamm B, Maurer MH.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):72-82. doi: 10.1007/s00259-011-1935-5. Epub 2011 Sep 17.

PMID:
21927931
5.

Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.

Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A.

Eur Radiol. 2011 Nov;21(11):2408-16. doi: 10.1007/s00330-011-2199-y. Epub 2011 Jul 13.

PMID:
21750886
6.

Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.

Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Müller M, Brendle C, Werner MK, Claussen CD, Pfannenberg C.

Cancer Imaging. 2013 Mar 5;13:63-72. doi: 10.1102/1470-7330.2013.0007.

7.

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9.

8.

The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.

Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE.

Ann Surg. 2010 Nov;252(5):850-6. doi: 10.1097/SLA.0b013e3181fd37e8.

PMID:
21037441
9.

Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.

Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM.

Eur Radiol. 2016 Mar;26(3):900-9. doi: 10.1007/s00330-015-3882-1. Epub 2015 Jul 12.

PMID:
26162577
10.

Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography.

Kitano M, Kudo M, Yamao K, Takagi T, Sakamoto H, Komaki T, Kamata K, Imai H, Chiba Y, Okada M, Murakami T, Takeyama Y.

Am J Gastroenterol. 2012 Feb;107(2):303-10. doi: 10.1038/ajg.2011.354. Epub 2011 Oct 18.

PMID:
22008892
11.

Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.

Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazère J, Nunes ML, Smith D, Hindié E, Fernandez P, Tabarin A.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1258-66. doi: 10.1007/s00259-016-3319-3. Epub 2016 Jan 28.

PMID:
26819103
12.

Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?

Mayerhoefer ME, Schuetz M, Magnaldi S, Weber M, Trattnig S, Karanikas G.

Eur Radiol. 2012 Apr;22(4):938-46. doi: 10.1007/s00330-011-2328-7. Epub 2011 Nov 12.

PMID:
22080251
13.

Pre-operative Diagnosis of Pancreatic Neuroendocrine Tumors with Endoscopic Ultrasonography and Computed Tomography in a Large Series.

Manta R, Nardi E, Pagano N, Ricci C, Sica M, Castellani D, Bertani H, Piccoli M, Mullineris B, Tringali A, Marini F, Germani U, Villanacci V, Casadei R, Mutignani M, Conigliaro R, Bassotti G, Zullo A.

J Gastrointestin Liver Dis. 2016 Sep;25(3):317-21. doi: 10.15403/jgld.2014.1121.253.ned.

14.

Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.

Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.

J Nucl Med. 2017 Mar;58(3):451-457. doi: 10.2967/jnumed.116.180430. Epub 2016 Sep 22.

PMID:
27660147
15.

Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.

Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H.

Neuroendocrinology. 2010;91(1):101-9. doi: 10.1159/000265561. Epub 2009 Dec 9.

PMID:
19996582
16.

Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.

Jindal T, Kumar A, Venkitaraman B, Dutta R, Kumar R.

Korean J Intern Med. 2010 Dec;25(4):386-91. doi: 10.3904/kjim.2010.25.4.386. Epub 2010 Nov 27.

17.

Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.

Flechsig P, Zechmann CM, Schreiweis J, Kratochwil C, Rath D, Schwartz LH, Schlemmer HP, Kauczor HU, Haberkorn U, Giesel FL.

Eur J Radiol. 2015 Aug;84(8):1593-1600. doi: 10.1016/j.ejrad.2015.04.009. Epub 2015 May 8.

PMID:
25999064
18.

Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.

Prasad V, Tiling N, Denecke T, Brenner W, Plöckinger U.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):2014-20. doi: 10.1007/s00259-016-3421-6. Epub 2016 Jun 13.

PMID:
27293206
19.

Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia.

Froeling V, Elgeti F, Maurer MH, Scheurig-Muenkler C, Beck A, Kroencke TJ, Pape UF, Hamm B, Brenner W, Schreiter NF.

Ann Nucl Med. 2012 Nov;26(9):738-43. doi: 10.1007/s12149-012-0634-z. Epub 2012 Aug 4.

PMID:
22865406
20.

Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.

Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):68-75.

Supplemental Content

Support Center